HK Stock Market Move | CH MODERN D(01117) rises over 9% again, increasing its stake in CHINA SHENGMU to over 83%. The total number of dairy cows accounts for 10% of the national inventory.
Modern Dairy (01117) has risen over 9% again, with a cumulative increase of more than 90% since June 26. As of the time of publication, it has risen 8.52% to HKD 1.72, with a trading volume of HKD 104 million.
CH MODERN D (01117) has risen by over 9%, with a cumulative increase of more than 90% from June 26 to the present. As of the time of writing, it has risen by 8.52%, priced at HKD 1.72, with a trading volume of HKD 104 million.
In news, CH MODERN D and CHINA SHENGMU jointly announced that the mandatory unconditional cash offer proposed by CH MODERN D has closed. CH MODERN D and its concert parties collectively hold approximately 7 billion shares, accounting for about 83.52% of the issued share capital. Following the acquisition, CH MODERN D and CHINA SHENGMU will have a total dairy cow inventory of 604,000 head, representing 10.4% of the national total inventory.
In addition, CH MODERN D recently released a positive profit forecast, estimating that the pre-tax profit for the first half of the year will not be less than HKD 43 million, which marks a turnaround from loss to profit year-on-year. Huaxi pointed out that the positive profit forecast for the first half of the year significantly improves confidence in the full-year profit, transitioning from financial improvement on the reporting side to operational profit improvement. Furthermore, leading livestock companies turning losses into profits preliminarily reveal that the milk price cycle is entering a reversal phase.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





